Concepedia

Author

Jens Eilbracht

Boehringer Ingelheim (Germany)

Also Known As

J. Eilbracht, Jens Eilbracht, Katherine Tuttle

4

Publications

757

Citations

4

H-Index

5

Concepts

All Affiliations

Boehringer Ingelheim (Germany)Profil Institute for Metabolic ResearchMedical University of GrazBoehringer Ingelheim (Canada)Boehringer Ingelheim (France)
JE

About

Jens Eilbracht is an author at Boehringer Ingelheim (Germany) specializing in cardiovascular disease, diabetes, and pharmacotherapy.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

1

1

438

2

Diabetes

1

1

438

3

Pharmacology

1

1

438

4

Cardiovascular Disease

1

1

438

5

Pharmacotherapy

1

1

438

Jens Eilbracht

×

3

Publications

652

Citations

3

H-Index

YearCitations

Empagliflozin monotherapy with sitagliptin as an active comparator in patients with type 2 diabetes: a randomised, double-blind, placebo-controlled, phase 3 trial

Michael Roden, Jianping Weng, Jens Eilbracht,

The Lancet Diabetes & Endocrinology

2013

438

Empagliflozin as adjunct to insulin in patients with type 1 diabetes: a 4‐week, randomized, placebo‐controlled trial ( <scp>EASE</scp> ‐1)

Thomas R. Pieber, Susanne Famulla, Jens Eilbracht,

Diabetes Obesity and Metabolism

2015

162

Glucose Exposure and Variability with Empagliflozin as Adjunct to Insulin in Patients with Type 1 Diabetes: Continuous Glucose Monitoring Data from a 4-Week, Randomized, Placebo-Controlled Trial (EASE-1)

Susanne Famulla, Thomas R. Pieber, Jens Eilbracht,

Diabetes Technology & Therapeutics

2016

52

Page 1